Home
 »  News
 »  Feature_Story
 »  Vioxx: An Alternative for Those with Osteoarthritis
KNEE1 NEWS: Feature Story
Printer Friendly Version     Email this Article     Links/Reuse

Vioxx: An Alternative for Those with Osteoarthritis


May 11, 2000 |  By Lindsey Christie, Knee1 Staff

Vioxx has become one of the fastest-selling drugs in the world. The FDA approved Vioxx in May of 1999 for the treatment of osteoarthritis (OA), menstrual pain, and the management of acute pain in adults. Drug sales have soared since last spring, and reports indicate that more than 6 million Americans are currently taking Vioxx.

Osteoarthritis (OA) is the most common form of arthritis. According to the American Medical Association it affects more than 16 million Americans. It is a degenerative disease associated with wear and tear and it is mainly found in the elderly. People suffering with OA often have pain and a limited range of motion in one or both knees. This pain and inflammation causes significant discomfort and because there is no cure for arthritis, patients rely on medications such as aspirin, ibuprofen, naproxen, or other non-steroidal anti-inflammatory drugs (NSAIDS) to provide relief. Although NSAIDS may improve comfort levels they may also produce damaging effects such as stomach upset, gastrointestinal problems, bleeding and ulcers.

Vioxx is a new non-steroidal anti-inflammatory drug; it is the second drug approved in a class of drugs referred to as Cox-2 inhibitors. The Cox-2 inhibitors work in a similar manner to the traditional NSAIDS in blocking pain and inflammation, but studies show that they are less likely to produce stomach upset, ulcers or bleeding. Although the development of Cox-2 inhibitor drugs, such as Vioxx, is an exciting alternative for people suffering from OA, and other forms of acute pain, doctors state that it is not a miracle drug; it may help patients manage the disease but it will not change the course of the disease.

Vioxx has been well received by both physicians and patients and has reached $472 million in sales for the last year with estimates suggesting that sales may reach $2 billion or more by 2002. Merck & Co., the makers of Vioxx, hope to market this new drug to more than 2.1 million Americans who suffer from a chronic inflammatory disease known as rheumatoid arthritis. Clinical trials are currently underway to test for efficacy and safety of Vioxx in individuals who have been diagnosed with rheumatoid arthritis.

Bookmark and Share

Previous Stories

Hardaway, Ewing Overcome Injuries

Unicompartmental Knee Replacement: A New Approach

Bourque to miss Game 4 against Red Wings

more Feature Stories


RSS  

Forgot information?
Login problem??

Take That Hill Down a Peg
By
more more Blogs RSS

Meet in the FORUMS
Lateral Patellofemoral Compression Syndrome
By cgaffney

Posted: Feb 10, 2012
I haven't had that surgery before, but I hope that this helps:http://www.knee1.com/Care_Tools/Preparing_for_SurgeryI wanted to refer you to that just in case no one who has had the surgery sees your p

more more Forums
Create a Topic

Osteoarthritis
Osteoarthritis Overview
Listen as Doctor Thomas P. Sculco, Surgeon-in-Chief at the Hospital for Special Surgery in New York, explains what osteoarthritis is and the condition's common symptoms. ...
more more Featured Videos

Dr. Cynthia LaBella
 

Dr. Cynthia LaBella:
Preventing Knee Injuries in Young Athletes

more more Heroes
Nominate a Hero Hero Policy
Home | About Us | Press | Make a Suggestion | Content Syndication | Terms of Service
Privacy Policy | Advertising Policy | Editorial Policy
Last updated: Sep 19, 2011  ©1999- 2012 Body1 All rights reserved.